FTFinancial Times·18hBusiness
score+0.60
Samsung Biologics buys Swiss peptide maker for $1.8bn
Original
Samsung Biologics buys Swiss peptide maker for $1.8bn
“Acquisition framed as strategic business expansion with neutral financial details and positive growth implications for the acquirer.”